Bevirimat, the prototype Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor, is highly potent in cell culture and efficacious in HIV-1 infected patients. Maturation inhibitors are an experimental class of antiretrovirals that inhibit Human Immunodeficiency Virus (HIV) particle maturation, the structural rearrangement required to form infectious virus particles. Unlike protease inhibitors, Bevirimat (BVM) blocks the cleavage of the Gag capsid precursor (CA-SP1) to mature capsid (CA) protein, resulting in the release of immature, noninfectious viral particles. Bevirimat specifically inhibits a single cleavage event, the final processing step for the Gag precursor where p25 (CA-SP1) is cleaved to p24 (CA) and SP1. The protease-dependent bevirimat resistance and replication levels can be explained by differences in CA/p2 cleavage processing by the different proteases.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.
Dang et al. Bioorg Med Chem Lett. 2012 Aug 15;22(16):5190-4. PMID: 22818973.
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
Nguyen et al. Retrovirology. 2011 Dec 7;8:101. PMID: 22151792.
Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers.
Dybowski et al. BioData Min. 2011 Nov 14;4:26. PMID: 22082002.
HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Fun et al. Retrovirology. 2011 Aug 24;8:70. PMID: 21864346.
A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat.
Lu et al. Antimicrob Agents Chemother. 2011 Jul;55(7):3324-9. PMID: 21502630.
|Related HIV Protease Products|
BMS-626529 is a potent HIV-1 attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4(+) T cells.
Darunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy.
Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy.
Atazanavir is an azapeptide and HIV-protease inhibitor that is used in the treatment of HIV infections and AIDS in combination with other anti-HIV agents.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.